These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32633703)

  • 21. Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process.
    Valero S; López-Briz E; Vila N; Solana A; Melero M; Poveda JL
    Regul Toxicol Pharmacol; 2018 Jun; 95():1-7. PubMed ID: 29510165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of healthcare workers' exposure to cyclophosphamide, ifosfamide, methotrexate, and 5-fluorouracil by 24-h urine assay: A descriptive pilot study.
    Palamini M; Dufour A; Therrien R; Delisle JF; Mercier G; Gagné S; Caron N; Bussières JF
    J Oncol Pharm Pract; 2020 Dec; 26(8):1864-1870. PubMed ID: 32138611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the efficacy of a self-cleaning automated compounding system for the decontamination of cytotoxic drugs.
    Telleria N; García N; Grisaleña J; Algaba N; Bergareche E; Tamés MJ; Cajaraville G
    J Oncol Pharm Pract; 2021 Sep; 27(6):1343-1353. PubMed ID: 32854575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures.
    Sessink PJ; Wittenhorst BC; Anzion RB; Bos RP
    Arch Environ Health; 1997; 52(3):240-4. PubMed ID: 9169636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 66 Canadian hospitals: A 2016 follow-up study.
    Roland C; Caron N; Bussières JF
    J Occup Environ Hyg; 2017 Aug; 14(8):661-669. PubMed ID: 28574754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of occupational exposure to antiblastic drugs in an Italian hospital oncological department.
    Castiglia L; Miraglia N; Pieri M; Simonelli A; Basilicata P; Genovese G; Guadagni R; Acampora A; Sannolo N; Scafarto MV
    J Occup Health; 2008; 50(1):48-56. PubMed ID: 18285644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Two Cleaning Solutions for the Decontamination of 10 Antineoplastic Agents in the Biosafety Cabinets of a Hospital Pharmacy.
    Anastasi M; Rudaz S; Queruau Lamerie T; Odou P; Bonnabry P; Fleury-Souverain S
    Ann Occup Hyg; 2015 Aug; 59(7):895-908. PubMed ID: 25979920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of an Environmental Monitoring to Assess the Practices and Control the Risk of Occupational Exposure to Cyclophosphamide in Two Sites of a French Comprehensive Cancer Center.
    Acramel A; Fouque J; Blondeel-Gomes S; Huguet S; Rezai K; Madar O; Escalup L
    Ann Work Expo Health; 2022 Nov; 66(9):1215-1223. PubMed ID: 35596678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence to Precautionary Guidelines for Compounding Antineoplastic Drugs: A Survey of Nurses and Pharmacy Practitioners.
    Boiano JM; Steege AL; Sweeney MH
    J Occup Environ Hyg; 2015; 12(9):588-602. PubMed ID: 25897702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning.
    Chu WC; Hon CY; Danyluk Q; Chua PP; Astrakianakis G
    J Oncol Pharm Pract; 2012 Mar; 18(1):46-51. PubMed ID: 21737485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antineoplastic agent workplace contamination study: the Alberta Cancer Board Pharmacy perspective Phase III.
    Bigelow S; Schulz H; Dobish R; Chambers CR
    J Oncol Pharm Pract; 2009 Sep; 15(3):157-60. PubMed ID: 19171554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals.
    Poupeau C; Tanguay C; Caron NJ; Bussières JF
    J Oncol Pharm Pract; 2018 Jan; 24(1):9-17. PubMed ID: 27799608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antineoplastic agent workplace contamination study: the Alberta Cancer Board Pharmacy perspective.
    Schulz H; Bigelow S; Dobish R; Chambers CR
    J Oncol Pharm Pract; 2005 Sep; 11(3):101-9. PubMed ID: 16390598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Occupational exposure to antineoplastic drugs in four Italian health care settings.
    Sottani C; Porro B; Imbriani M; Minoia C
    Toxicol Lett; 2012 Aug; 213(1):107-15. PubMed ID: 21477641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs.
    Bartel SB; Tyler TG; Power LA
    Am J Health Syst Pharm; 2018 Feb; 75(4):199-211. PubMed ID: 29339374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicenter study of environmental contamination with antineoplastic drugs in 33 Canadian hospitals.
    Merger D; Tanguay C; Langlois E; Lefebvre M; Bussières JF
    Int Arch Occup Environ Health; 2014 Apr; 87(3):307-13. PubMed ID: 23471647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of surface contamination in a hospital hematology--oncology pharmacy.
    Touzin K; Bussières JF; Langlois E; Lefebvre M
    J Oncol Pharm Pract; 2009 Mar; 15(1):53-61. PubMed ID: 18772214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Occupational exposure to cytotoxic drugs in two UK oncology wards.
    Ziegler E; Mason HJ; Baxter PJ
    Occup Environ Med; 2002 Sep; 59(9):608-12. PubMed ID: 12205233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaporation of selected cytotoxic drugs and permeation of protective gloves--research into the occupational risks of health care personnel handling hazardous cytotoxic drugs (CYTO project)].
    Dolezalová L; Odráska P; Gorná L; Prudilová M; Vejpustková R; Bláha L
    Klin Onkol; 2009; 22(5):218-22. PubMed ID: 19886359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of closed system transfer devices for turnaround time and ease of use.
    Nurgat ZA; Lawrence M; Elhassan TA; Al Nahedh M; Ashour M; Alaboura D; Al-Jazairi AS; Al-Jedai A
    J Oncol Pharm Pract; 2019 Jul; 25(5):1142-1151. PubMed ID: 29958506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.